Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Carlyle schedules third-quarter earnings release, investor call

Carlyle schedules third-quarter earnings release, investor call

BitgetBitget2026/10/05 12:59

Carlyle schedules third-quarter 2026 results release for Nov. 5, 2026. Investor conference call set for Nov. 5, 2026 at 8:30 a.m. EST, with webcast via ir.carlyle.com. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Carlyle Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050859PRIMZONEFULLFEED9839533) on October 05, 2026, and is solely responsible for the information contained therein.

  • Carlyle schedules third-quarter 2026 results release for Nov. 5, 2026.
  • Investor conference call set for Nov. 5, 2026 at 8:30 a.m. EST, with webcast via ir.carlyle.com.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Carlyle Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050859PRIMZONEFULLFEED9839533) on October 05, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

UBS: Resumes coverage of Regeneron Pharmaceuticals (REGN.US) with a "Buy" rating; potential of blockbuster drug Dupixent underestimated

UBS has resumed coverage of Regeneron Pharmaceuticals (REGN.US) with a "Buy" rating and a target price of $978.

智通财经•2026/10/15 06:46

IMF sounds the alarm: Energy shocks and rising US Treasury yields pose spillover risks, Asia’s growth may slow to 4.4% next year

The IMF has lowered its growth forecast for Asia to 4.4% for next year, warning of three major risks: energy shocks, a correction in the AI boom, and rising global yields. The IMF also urged central banks to focus on price stability and avoid broad-based fuel subsidies.

智通财经•2026/10/15 06:46
IMF sounds the alarm: Energy shocks and rising US Treasury yields pose spillover risks, Asia’s growth may slow to 4.4% next year